Litcius/Paper detail

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial

Lina Jin, Siyu Gu, Qianqi Ruan, Jing Lu, Wanting Qiang, Haiyan He, Xiaoqiang Fan, Jin Liu, Pei Guo, Xingxing Meng, Nishanthan Rajakumaraswamy, Deng Chen, Zonghai Li, Juan Du

2025The Lancet Haematology7 citationsDOI

Topics & Concepts

MedicineRefractory (planetary science)Clinical trialInternal medicinePhases of clinical researchOncologyIntensive care medicineMEDLINESurgeryGuidelineChemotherapyNatural historyPhase (matter)Emergency medicineIncidence (geometry)ChinaCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsCutaneous lymphoproliferative disorders research
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial | Litcius